<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bhattacharya S</submitter><funding>Regional Centre for Biotechnology</funding><funding>Baylor College of Medicine</funding><funding>Department of Biotechnology, Ministry of Science and Technology, India</funding><pagination>103418</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8190441</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>68</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>We have previously described an evolutionarily selected Tibetan prolyl hydroxylase-2 (PHD2&lt;sup>D4E;C127S&lt;/sup>) variant that degrades the hypoxia-inducible factor (HIFα) more efficiently and protects these highlanders from hypoxia-triggered elevation in haemoglobin concentration. High altitude is known to cause acute mountain sickness (AMS) and high-altitude pulmonary edema (HAPE) in a section of rapidly ascending non-acclimatised lowlanders. These morbidities are often accompanied by inflammatory response and exposure to hypobaric hypoxia is presumed to be the principal causative agent. We have investigated whether PHD2&lt;sup>D4E;C127S&lt;/sup> variant is associated with prevention of hypoxia-mediated inflammatory milieu in Tibetan highlanders and therefore identify a potent</pubmed_abstract><journal>EBioMedicine</journal><pubmed_title>Gain-of-function Tibetan PHD2&lt;sup>D4E;C127S&lt;/sup> variant suppresses monocyte function: A lesson in inflammatory response to inspired hypoxia.</pubmed_title><pmcid>PMC8190441</pmcid><funding_grant_id>BT/PR22985</funding_grant_id><pubmed_authors>Shrimali NM</pubmed_authors><pubmed_authors>Mohammad G</pubmed_authors><pubmed_authors>Guchhait P</pubmed_authors><pubmed_authors>Bhattacharya S</pubmed_authors><pubmed_authors>Koul PA</pubmed_authors><pubmed_authors>Prchal JT</pubmed_authors></additional><is_claimable>false</is_claimable><name>Gain-of-function Tibetan PHD2&lt;sup>D4E;C127S&lt;/sup> variant suppresses monocyte function: A lesson in inflammatory response to inspired hypoxia.</name><description>&lt;h4>Background&lt;/h4>We have previously described an evolutionarily selected Tibetan prolyl hydroxylase-2 (PHD2&lt;sup>D4E;C127S&lt;/sup>) variant that degrades the hypoxia-inducible factor (HIFα) more efficiently and protects these highlanders from hypoxia-triggered elevation in haemoglobin concentration. High altitude is known to cause acute mountain sickness (AMS) and high-altitude pulmonary edema (HAPE) in a section of rapidly ascending non-acclimatised lowlanders. These morbidities are often accompanied by inflammatory response and exposure to hypobaric hypoxia is presumed to be the principal causative agent. We have investigated whether PHD2&lt;sup>D4E;C127S&lt;/sup> variant is associated with prevention of hypoxia-mediated inflammatory milieu in Tibetan highlanders and therefore identify a potent</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2026-05-08T23:09:09.958Z</modification><creation>2022-02-10T15:20:23.16Z</creation></dates><accession>S-EPMC8190441</accession><cross_references><pubmed>34102396</pubmed><doi>10.1016/j.ebiom.2021.103418</doi></cross_references></HashMap>